Literature DB >> 18703164

Two-stage designs for phase II cancer trials with ordinal responses.

Nigel Stallard1, Louise Cockey.   

Abstract

A common approach to the design of phase II clinical trials in oncology is to conduct a two-stage trial so as to control type I and type II error rates. A number of researchers have proposed methods for the design of such trials when the response can take one of a number of ordered values such as tumor response, stable disease or progressive disease. In this case, the problem may be formulated as that of testing a complex null hypothesis. Control of the type I error rate thus requires specification of the null region and construction of a test that limits the maximum error rate over this region. In this paper we propose that the null region should be bounded by a line in the two-dimensional parameter space for the setting with a response with three levels and more generally by a plane or hyperplane. We then propose a test based on the likelihood ratio statistic and show how this may be calculated in this case for a three-level response. The method is illustrated using an example of a clinical trial to evaluate a new treatment for breast cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18703164     DOI: 10.1016/j.cct.2008.07.003

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  1 in total

1.  Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.

Authors:  Guan-Zhong Zhang; Shun-Chang Jiao; Zhao-Ting Meng
Journal:  J Exp Clin Cancer Res       Date:  2010-04-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.